Physician profile
Carmel Moazez
NPI 1144683509
$4,739.72
in general payments reported to CMS, 2019-2025
12 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.42 · 2022: $513 · 2023: $3,028 · 2024: $381 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569 · Travel and Lodging: $1,408 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.10 |
| Travel and Lodging | $1,408.48 |
| Education | $232.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,391.42 | 2023 | Ensite Precision, Ensite |
| Abiomed | $451.17 | 2022-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $378.82 | 2022-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $324.99 | 2021-2025 | Linq II, Selectsecure, Cobalt Dr Mri Surescan |
| Amgen INC. | $323.35 | 2025 | Repatha |
| Boston Scientific Corporation | $288.22 | 2022-2024 | Emblem Mri S-Icd |
| Cvrx, INC. | $186.13 | 2022-2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $147.12 | 2023-2025 | |
| Chiesi USA, INC. | $83.64 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.18 | 2025 | Lifevest |
| Lilly USA, LLC | $45.00 | 2025 | |
| Alnylam Pharmaceuticals INC. | $36.68 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmel Moazez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.